May 26, 2021 -- Citing a successful cohort study of patients, Cellaria has launched five new lung cancer cell models to support the development of more effective and targeted drug therapies.
Each model is linked to a patient tumor, enabling the in vitro study of disease progression and drug response in a specific patient biology with defined genetic and epigenetic characteristics. Cellaria's lung cancer cell models are all derived from tumors associated with nonsmall cell lung cancer, which accounts for about 85% of lung cancer cases.
All models are supplied with a certificate of analysis to support optimal application. In addition, Cellaria produces drug response reports showing data for three baseline relevant treatments. For the lung cancer cohort, the report includes results for etoposide and cisplatin and for two targeted treatments. These include larotrectinib, which is prescribed for patients with a neurotrophic receptor tyrosine kinase gene fusion, and erlotinib, which is prescribed for patients with a KRAS mutation.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
